FDA advisory panel declines to support a controversial Alzheimer’s treatment
The drug, aducanumab, is made by pharmaceutical company Biogen
Pharmaceutical company Biogen is developing a drug that promises to slow, but not stop or reverse, the march of Alzheimer’s in the brain. But not all scientists are convinced that the drug works.
Kristoffer Tripplaar/Alamy